D. Western Therapeutics Institute, Inc. (TYO:4576)
Japan · Delayed Price · Currency is JPY 88.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
TYO:4576 Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 247 | 387 | 471 | 428 | 448 | 414 | |
Revenue Growth | -41.33% | -17.83% | 10.05% | -4.46% | 8.21% | 16.62% |
Cost of Revenue | 21 | 39 | 47 | 36 | 28 | 21 |
Gross Profit | 226 | 348 | 424 | 392 | 420 | 393 |
Selling, General & Admin | 281 | 298 | 265 | 258 | 255 | 248 |
Research & Development | 568 | 669 | 1,367 | 930 | 469 | 316 |
Operating Expenses | 851 | 968 | 1,634 | 1,190 | 726 | 565 |
Operating Income | -625 | -620 | -1,210 | -798 | -306 | -172 |
Interest Expense | -11 | -8 | -5 | -2 | -3 | -4 |
Interest & Investment Income | 4 | 2 | - | - | - | - |
Currency Exchange Gain (Loss) | 10 | 7 | 1 | 6 | 33 | 17 |
Other Non Operating Income (Expenses) | -16 | -12 | -13 | -2 | -20 | - |
EBT Excluding Unusual Items | -638 | -631 | -1,227 | -796 | -296 | -159 |
Gain (Loss) on Sale of Investments | - | - | - | -12 | -100 | - |
Gain (Loss) on Sale of Assets | - | - | -2 | - | - | - |
Asset Writedown | - | - | - | -6 | - | - |
Legal Settlements | - | - | - | - | -44 | - |
Other Unusual Items | - | - | -60 | -12 | - | - |
Pretax Income | -638 | -631 | -1,289 | -826 | -440 | -159 |
Income Tax Expense | 1 | 1 | 1 | 1 | 1 | 1 |
Earnings From Continuing Operations | -639 | -632 | -1,290 | -827 | -441 | -160 |
Minority Interest in Earnings | - | - | - | 15 | 12 | 12 |
Net Income | -639 | -632 | -1,290 | -812 | -429 | -148 |
Net Income to Common | -639 | -632 | -1,290 | -812 | -429 | -148 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 53 | 48 | 35 | 32 | 30 | 29 |
Shares Outstanding (Diluted) | 53 | 48 | 35 | 32 | 30 | 29 |
Shares Change | 29.06% | 36.48% | 10.51% | 7.22% | 1.04% | 7.96% |
EPS (Basic) | -11.97 | -13.19 | -36.73 | -25.55 | -14.47 | -5.05 |
EPS (Diluted) | -11.97 | -13.19 | -36.73 | -25.55 | -14.47 | -5.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -631 | -495 | -1,308 | -598 | -363 | -178 |
Free Cash Flow Per Share | -11.81 | -10.33 | -37.24 | -18.82 | -12.25 | -6.07 |
Gross Margin | 91.50% | 89.92% | 90.02% | 91.59% | 93.75% | 94.93% |
Operating Margin | -253.04% | -160.21% | -256.90% | -186.45% | -68.30% | -41.55% |
Profit Margin | -258.70% | -163.31% | -273.88% | -189.72% | -95.76% | -35.75% |
Free Cash Flow Margin | -255.47% | -127.91% | -277.71% | -139.72% | -81.03% | -42.99% |
EBITDA | -599 | -573 | -1,161 | -750 | -260 | -127 |
EBITDA Margin | -242.51% | -148.06% | -246.50% | -175.23% | -58.04% | -30.68% |
D&A For EBITDA | 26 | 47 | 49 | 48 | 46 | 45 |
EBIT | -625 | -620 | -1,210 | -798 | -306 | -172 |
EBIT Margin | -253.04% | -160.21% | -256.90% | -186.45% | -68.30% | -41.55% |